Business
Northern Vine Labs Expands Dealer’s License with Health Canada
Northern Vine Labs Expands Dealer’s License with Health Canada.
About this update from Abattis Bioceuticals Corp
[{"type":"text","content":"\n\n VICTORIA, B.C., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Northern Vine Labs (“Company”), a subsidiary of Emerald Health Therapeutics Inc. (“Emerald”) (TSXV:EMH) (OTCQX:EMHTF) and Abattis Bioceuticals Corp. (“Abattis”) (CSE:ATT) (OTC:ATTBF), today announced that Health Canada has approved an amendment to the Company’s dealer’s license.\n The license amendment provides the Company the ability to transport, deliver and sell product to other Licensed Dealers (LD), authorized persons under the Controlled Drug and Substance Act (CDSA), and Licensed Producers (LP). Along with the Company’s already authorized activities for analytical testing, extraction, and import/export, this amendment also allows Northern Vine Labs to broaden its business opportunities through the production and sale of downstream cannabis products. “This amendment helps expand the business potential of our dealer’s license,” said Avtar Dhillon, MD, Executive Chairman of Emerald. “With the new Proposed Approach to the Regulation of Cannabis released by the Government of Canada, we believe Northern Vine Labs is in a unique position to become a leader in the analytical, international processing, and R&D segments of the cannabis market.” Northern Vine is a Licensed Dealer under the provisions of the Canadian Controlled Drugs and Substances Act. An LD is permitted to carry out certain business activities that Emerald is not permitted to undertake as an LP under Access to Cannabis for Medical Purpose Regulations (“CMPR), including the import/export of cannabis and cannabis oils, as well as the manipulation, formulation, dosage form, strength or package size of cannabis, including mixtures with other additives, controlled substances, and non-controlled substances. These opportunities expand possible research and product innovation opportunities for Emerald. Emerald acquired 53% of Northern Vine from Abattis in November, 2017. About Emerald Health Therapeutics Inc. Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) operates through Emerald Health Botanicals Inc. (\"Botanicals\"), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through Botanicals, Emerald is authorized to produce and sell dried medical ...